Different HTLV-I neutralization patterns among sera of patients infected with cosmopolitan HTLV-I

被引:10
作者
Blanchard, S
Astier-Gin, T
Moynet, D
Edouard, E
Guillemain, B
机构
[1] Univ Bordeaux 2, Inst Bergonie, INSERM, U328, F-33076 Bordeaux, France
[2] Univ Quebec, Dept Sci Biol, Montreal, PQ H3C 3P8, Canada
关键词
D O I
10.1006/viro.1998.9139
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
To determine if sequence variations observed in cosmopolitan HTLV-I interfered with viral recognition by neutralizing antibodies, we evaluated the neutralization potential of sera from persons infected by HTLV-I of this clade selected for amino acid changes in their env glycoproteins. Each serum was used to neutralize three previously described HTLV-I isolates, 2060, 2072, and 1010, that possess amino acid env sequences differing at several positions, one of them being located in the immunodominant and neutralizable domain (aa 187-199). The results obtained in syncytia and/or reporter gene inhibition assays showed that the neutralization pattern of the sera clearly differed and could be classified in three categories. Five sera completely neutralized the three viruses with an equivalent titer, two sera gave a maximum inhibition, with higher ID50 on the 2072 virus than on the 2060 or 1010 viruses, and three sera had a stronger neutralization potential toward the 1010 virus than toward the 2060 virus. One of these sera partially neutralized the virus produced by 2072 cells, whereas neutralizing antibodies in the other two recognized the neutralizable epitopes on the 1010 or 2072 viruses equally well. identification of amino acid sequences involved in induction of neutralizing antibodies with different recognition capacities could help identify new neutralizable epitopes of HTLV-I envelope glycoproteins and to better define the component(s) of an effective vaccine. (C) 1998 Academic Press.
引用
收藏
页码:90 / 98
页数:9
相关论文
共 43 条
[1]   Neutralizing activity and antibody reactivity toward immunogenic regions of the human T cell leukemia virus type I surface glycoprotein in sera of infected patients with different clinical states [J].
AstierGin, T ;
Portail, JP ;
LondosGagliardi, D ;
Moynet, D ;
Blanchard, S ;
Dalibart, R ;
Pouliquen, JF ;
GeorgesCourbot, MC ;
Hajjar, C ;
SainteFoie, S ;
Guillemain, B .
JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (03) :716-719
[2]   IDENTIFICATION OF HTLV-I-PRODUCING OR HTLV-II-PRODUCING CELLS BY COCULTIVATION WITH BHK-21-CELLS STABLY TRANSFECTED WITH A LTR-LACZ GENE CONSTRUCT [J].
ASTIERGIN, T ;
PORTAIL, JP ;
LAFOND, F ;
GUILLEMAIN, B .
JOURNAL OF VIROLOGICAL METHODS, 1995, 51 (01) :19-29
[3]  
BABA E, 1995, J IMMUNOL, V154, P399
[4]   CROSS-NEUTRALIZING ANTIBODIES AGAINST COSMOPOLITAN AND MELANESIAN STRAINS OF HUMAN T-CELL LEUKEMIA/LYMPHOTROPIC VIRUS TYPE-I IN SERA FROM INHABITANTS OF AFRICA AND THE SOLOMON-ISLANDS [J].
BENSON, J ;
TSCHACHLER, E ;
GESSAIN, A ;
YANAGIHARA, R ;
GALLO, RC ;
FRANCHINI, G .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 (01) :91-96
[5]   PSEUDOTYPES OF HUMAN T-CELL LEUKEMIA-VIRUS TYPE-1 AND TYPE-2 - NEUTRALIZATION BY PATIENTS SERA [J].
CLAPHAM, P ;
NAGY, K ;
WEISS, RA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1984, 81 (09) :2886-2889
[6]   INFLUENCE OF TRANSMEMBRANE DOMAINS ON THE FUSOGENIC ABILITIES OF HUMAN AND MURINE LEUKEMIA RETROVIRUS ENVELOPES [J].
DENESVRE, C ;
SONIGO, P ;
CORBIN, A ;
ELLERBROK, H ;
SITBON, M .
JOURNAL OF VIROLOGY, 1995, 69 (07) :4149-4157
[7]  
DEZZUTTI CS, 1990, CANCER RES, V50, pS5687
[8]  
EDOUARD E, 1994, LEUKEMIA, V8, pS65
[9]   CHARACTERIZATION OF THE ANTIBODY-RESPONSE TO 3 DIFFERENT VERSIONS OF THE HTLV-I ENVELOPE PROTEIN EXPRESSED BY RECOMBINANT VACCINIA VIRUSES - INDUCTION OF NEUTRALIZING ANTIBODY [J].
FORD, CM ;
ARP, J ;
PALKER, TJ ;
KING, EE ;
DEKABAN, GA .
VIROLOGY, 1992, 191 (01) :448-453
[10]  
GESSAIN A, 1985, LANCET, V2, P407